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Introduction: Immunological markers have been described during COVID-19 and persist 
after recovery. These immune markers are associated with clinical features among SARS-
CoV-2 infected individuals. Nevertheless, studies reporting a comprehensive analysis of the 
immune changes occurring during SARS-CoV-2 infection are still limited. 
Objective: To evaluate the production of proinflammatory cytokines, the antibody response, 
and the phenotype and function of NK cells and T cells in a Colombian family cluster with 
SARS-CoV-2 infection. 
Materials and methods: Proinflammatory cytokines were evaluated by RT-PCR and ELISA. 
The frequency, phenotype, and function of NK cells (cocultures with K562 cells) and T-cells 
(stimulated with spike/RdRp peptides) were assessed by flow cytometry. Anti-SARS-CoV-2 
antibodies were determined using indirect immunofluorescence and plaque reduction 
neutralization assay. 
Results: During COVID-19, we observed a high proinflammatory-cytokine production and a 
reduced CD56bright-NK cell and cytotoxic response. Compared with healthy controls, infected 
individuals had a higher frequency of dysfunctional CD8+ T cells CD38+HLA-DR-. During the 
acute phase, CD8+ T cells stimulated with viral peptides exhibited a monofunctional response 
characterized by high IL-10 production. However, during recovery, we observed a bifunctional 
response characterized by the co-expression of CD107a and granzyme B or perforin.
Conclusion: Although the proinflammatory response is a hallmark of SARS-CoV-2 
infection, other phenotypic and functional alterations in NK cells and CD8+ T cells could 
be associated with the outcome of COVID-19. However, additional studies are required to 
understand these alterations and to guide future immunotherapy strategies. 
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Caracterización inmunológica de un grupo familiar colombiano con infección por 
SARS-CoV-2
Introducción. Se han descrito diferentes marcadores inmunológicos durante la COVID-19, 
los cuales persisten incluso después de la convalecencia y se asocian con los estadios 
clínicos de la infección. Sin embargo, aún son pocos los estudios orientados al análisis 
exhaustivo de las alteraciones del sistema inmunológico en el curso de la infección.
Objetivo. Evaluar la producción de citocinas proinflamatorias, la reacción de anticuerpos, 
y el fenotipo y la función de las células NK y los linfocitos T en una familia colombiana con 
infección por SARS-CoV-2.
Materiales y métodos. Se evaluaron las citocinas proinflamatorias mediante RT-PCR y 
ELISA; la frecuencia, el fenotipo y la función de las células NK (en cocultivos con células 
K562) y linfocitos T CD8+ (estimulados con péptidos spike/RdRp) mediante citometría de 
flujo, y los anticuerpos anti-SARS-CoV-2, mediante inmunofluorescencia indirecta y prueba 
de neutralización por reducción de placa.
Resultados. Durante la COVID-19 hubo una producción elevada de citocinas 
proinflamatorias, con disminución de las células NK CD56bright y reacción citotóxica. 
Comparados con los controles sanos, los individuos infectados presentaron con gran 
frecuencia linfocitos T CD8+ disfuncionales CD38+HLA-DR-. Además, en los linfocitos T 
CD8+ estimulados con péptidos virales, predominó una reacción monofuncional con gran 
producción de IL-10 durante la fase aguda y una reacción bifuncional caracterizada por la 
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Conclusión. Aunque la reacción inflamatoria caracteriza la infección por SARS-CoV-2, 
hay otras alteraciones fenotípicas y funcionales en células NK y linfocitos T CD8+ que 
podrían asociarse con la progresión de la infección. Se requieren estudios adicionales para 
entender estas alteraciones y guiar futuras estrategias de inmunoterapia.
Palabras clave: infecciones por coronavirus; inflamación; células asesinas naturales; 
linfocitos T; anticuerpos neutralizantes.
COVID-19 is caused by the severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2) (1). Currently, more than 212 million people have been infected 
with the virus worldwide. In Colombia, since the first reported case (March 6, 
2020), more than 4.8 million cases have been reported (by August 23, 2021).
SARS-CoV-2 is an enveloped, single-strand, positive-sense RNA virus (2). 
The infection begins with the interaction of the spike protein (S) with the cellular 
receptor ACE2, highly expressed on lower and upper respiratory tract cells, 
sites of viral transmission and severe disease development, respectively (3). 
Following infection, a strong inflammatory response is triggered including the 
high activity of macrophages and neutrophils and their products, reactive oxygen 
species (ROS), neutrophil extracellular traps (NETs), IL-6, type I IFN, monocyte 
chemoattractant protein (MCP-1), and human interferon-inducible protein (IP-10), 
among others (4,5). Systemic inflammation is a key feature, especially in those 
patients with severe clinical manifestations who exhibit increased levels of IL-6, 
TNFα, C reactive protein (CRP), and pro-coagulant factors (6,7).
NK cells are pivotal antiviral actors and can be rapidly recruited to different 
anatomical sites, such as the lungs, to assist the clearance of virus-infected 
cells. They are subdivided into several subpopulations according to CD56 
expression with the differential capacity to produce cytokines or induce 
apoptosis of target cells (8). NK cells are important players in the immune 
responses in COVID-19 patients by direct elimination of virus-infected cells 
and the modulation of the systemic inflammatory response (9). In addition, 
some NK cells subpopulations have similar features to adaptive T lymphocytes. 
In this sense, NKG2C+ NK cells can effectively mediate antibody-dependent 
effector functions and produce antiviral cytokines after peptide stimulation 
(10,12). Although studies are still limited in this field, COVID-19 patients exhibit 
NKG2A overexpression while activation markers are reduced, which suggests 
NK exhaustion and reduction of their response capacity (13).
Subsequent adaptive responses involving B and T cells are observed 
in infected patients, although humoral response seems to be variable. 
Detectable IgM and IgG antibodies are produced within days to weeks of the 
onset of symptoms in most infected individuals without there being a clear 
association between antibody responses and clinical outcome (14). However, 
some authors have reported stronger antibody response in those patients 
with severe symptoms (15). Both SARS-CoV-2-specific CD8+ and CD4+ T cells 
have been reported in the convalescence phase. But lymphopenia is often 
reported in severe and fatal cases suggesting a key role of adaptive cellular 
immunity in the control and outcome of SARS-CoV-2 infection (16). 
SARS-CoV-2-infected patients exhibit variable illness severity including 
asymptomatic infection, mild or severe disease, and, eventually, death. 
Although vaccination programs have been progressing adequately in many 
countries, in others coverage is still very limited. Thus, natural herd immunity 
should be considered as a potential mechanism against COVID-19, at least in 
particular community settings (i.e., small or country-side towns). Determining 
post-infection immunity has a key epidemiological and clinical value and 
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could also have implications in the evaluation of potential immunomodulatory 
therapies and vaccines. Here we provide a detailed functional and phenotypic 
characterization of immune parameters in a family cluster with SARS-CoV-2 
infection: Two asymptomatic cases and one patient with mild COVID-19. Our 
findings have important implications for understanding the circumstances 




The study on this family cluster (three individuals named JM, A, and JC) 
was approved by the institutional ethics board of Universidad de Antioquia 
(Colombia) and the informed consent was signed by all the family members in 
the study. 
The clinical data were collected by phone during their follow-up. A 
nasopharyngeal aspirate from JM was taken on March 25 for SARS-CoV-2 
detection by using the Luna® Universal Probe One-Step RT-qPCR Kit (New 
England Biolabs) and the CDC RT-PCR oligos and probes protocol (17). 
Furthermore, viral isolation was performed from the nasopharyngeal sample 
and the virus was amplified for the experiments (18). 
Blood samples were obtained on March 25 (acute phase), April 14 
(convalescent phase), and May 28 (recovery phase) from JM. Additionally, 
samples from A and JC were collected on May 28. Serum was obtained by 
centrifugation from anticoagulant-free and plasma from EDTA-blood and then 
stored at -80°C until their use for antibody testing by immunofluorescence 
and cytokine quantification by ELISA. Peripheral blood mononuclear cells 
(PBMCs) were isolated by EDTA blood centrifugation on a density gradient 
with Ficoll-Histopaque® (Sigma-Aldrich, St. Louis, MO, USA) and frozen in 
liquid nitrogen until immune assays. Also, fresh PBMC from three healthy 
donors age- and sex-matched with the family members were collected at the 
time of donors and included in some of the assays.
Quantification of inflammatory molecules by RT-PCR
Total RNA was isolated from PBMCs using the Direct-zol™ RNA Miniprep 
(Zymo Research., CA, USA), then quantified using a Multiskan SkyHigh 
Microplate Spectrophotometer (Thermo Fisher Scientific, Hanover, MD, USA), 
and cDNA synthesis was done with 150 ng of total RNA using the High-Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems™, CA, USA) following the 
manufacturers’ recommendations. The expression of IL-1β, IL-6, IL-8, and TNFα, 
as well as of the phosphoglycerate kinase (PGK) used as reference gene, was 
quantified by real-time RT-PCR using the Maxima SYBR® Green qPCR master 
mix (Thermo Fisher Scientific, Hanover, MD, USA), and a CFX-96 Real-Time 
thermal cycler (Bio-Rad, Hercules, CA, USA) as previously described (19). 
Oligos and thermal conditions are shown in supplementary material 1. Real-time 
RT-PCR analysis was conducted using the CFX Maestro 1.1 Software (Bio-Rad).
ELISA
Plasma levels of IL-1β, IL-6, and IL-8 were quantified in duplicate by ELISA 
using commercial kits from eBioscience (Vienna, Austria), BD Biosciences 
(Franklin Lakes, NJ), and Biolegend (San Diego, CA, USA), respectively, 
following the manufacturers’ instructions.
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NK cells phenotype by flow cytometry
Briefly, 1 x106 PBMCs were stained using monoclonal antibodies against 
CD45, CD56, CD3, CD57, and NKG2C for 25 minutes in the dark (antibody 
details are shown in supplementary material 2). Then, cells were washed 
twice with phosphate-buffered saline (PBS) (Lonza, Rockland, ME, USA), 
suspended in paraformaldehyde 2%, and acquired using LSR Fortessa™ 
(BD Biosciences, San Jose, CA, USA). The data were analyzed using FlowJo 
software, version 10.5.3 (FlowJo, LLC, Oregon, USA).
NK cytotoxicity assay
PBMCs were thawed and left in culture with RPMI (Sigma-Aldrich) 
supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) for 24 
h before the experiments. K562 cells were used as targets (20). Prior to 
culturing, 1×106 K562 cells were stained with 0.1 mM eFluor™ 670 (Thermo 
Fisher Scientific) in PBS for 10 min at 37°C. Then, PBMCs were co-cultured 
with K562 cells in round-bottomed tubes at a 10:1 ratio in 300 µl of RPMI with 
10% FBS for 4 h at 37°C and 5% CO2.
After incubation, cells were stained with propidium iodide (PI) and DIOC-
6 (both from Thermo Fisher Scientific) for 15 min in the dark. PI and DIOC-6 
were used to evaluate the integrity of the cell and mitochondrial membranes, 
respectively. K562 cells cultured in the absence of PBMCs were used as 
spontaneous death control, which was conducted for every assay. Spontaneous 
death control had to be lower than 15% for the experiment to be valid. The 
cytotoxicity percentage was adjusted based on spontaneous death control.
Anti-SARS-CoV-2 antibodies 
Indirect Immunofluorescence assay. Sera samples of all family members 
were subjected to indirect immunofluorescence assay (IFA) to determine the 
titer of specific antibodies against SARS-CoV-2.
Vero E6 monolayers grown in 75 cm2 flasks were infected or not 
with a Colombian SARS-CoV-2 isolate (SARS-CoV-2/human/Medellin/
UdeA1/2020) (20) at a multiplicity of infection (MOI) of 0.001 in 2 ml of DMEM 
supplemented with 2% FBS for 1 h; after virus adsorption, the inoculum was 
removed and replaced with fresh medium. Cells were detached with scrapper 
48 h.p.i and resuspended in 3 ml PBS. The cell suspension was spotted in 10 
well-immunofluorescence slides (20 ul/well) and dried overnight. Afterward, 
the slides were fixed by immersion in acetone for 30 min and stored at 4°C 
until used.
Two-fold dilutions of sera in PBS (1:5 to 1:80) were added to infected 
and uninfected cells (20 ul each) and incubated in a moist chamber at 37°C 
for 30 minutes, then washed twice by immersion in PBS for 5 min with slow 
shaking and then allowed to dry. After, 20 ul of anti-human IgG-FITC (Sigma-
Aldrich) diluted 1:16 in PBS were added to each well and incubated in a moist 
chamber at 37°C for 30 min followed by two washes. The slides were mounted 
with anti-fade reagent Fluosaver (Calbiochem) and coverslips and visualized 
in an Axio Vert.A1 (ZEISS, Oberkochen, Germany) fluorescent microscope at 
400x magnification by three different researchers. Antibody titer was reported 
as the last dilution where fluorescence was clearly observed in infected cells 
but no so at the same dilution in non-infected cells. Experiments requiring 
virus handling were done in a biosafety level 3 laboratory.
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Plaque reduction neutralization test. Neutralizing antibodies in the sera of 
infected individuals were tested using a 50% plaque reduction neutralization 
test (PRNT50) with Vero E6 cells. Briefly, Vero E6 cells (1.1 × 105 cells per 
well) were seeded into the 24-well tissue culture plates the day before 
infection. On the next day, 200 plaque-forming units of SARS-CoV-2 were 
incubated with or without serially diluted heat-inactivated sera (56°C, 30 
min) in a total volume of 200 μl in microcentrifuge tubes for 60 min at 37°C 
and 5% CO2. Next, the mixtures were added to Vero E6 monolayers and 
incubated at 37°C for 60 min. Then, the inoculum was removed and 1ml of 
the semisolid medium (containing 1.5% of carboxymethyl cellulose 2% fetal 
bovine serum, 1% streptomycin, and DMEM) was added and cultured at 
37°C for 72 h. Afterwards, the semisolid media was removed and monolayers 
were washed twice with PBS. Finally, monolayers were fixed and stained 
with 1% crystal violet/4% formaldehyde for 30 min and washed twice with 
PBS. A 50% reduction in plaque count (PRNT50) in two independent assays 
conducted by two different researchers was used as the neutralizing endpoint. 
The inhibition percentage was calculated based on the number of plaques on 
infection control wells. To discard toxicity, a serum control in uninfected cells 
per individual was also included in the assays. Experiments requiring virus 
handling were done in a biosafety level 3 laboratory.
T cell bBasal activation phenotype. Phenotypic analysis of PBMCs was 
done from frozen samples. T cells percentages and basal CD4+ and CD8+ T 
cell activation levels were assessed by flow cytometry. Cells were incubated 
with monoclonal antibodies against surface molecules CD4, CD8, HLA-
DR, CD69, and CD38 for 25 min. Then, cells were permeabilized and fixed 
using the Foxp3/Transcription Factor Staining kit (Thermo Fisher Scientific), 
and intracellular staining for 25 min with antibodies against Ki-67 and CD3 
was performed (see antibody details in supplementary material 2). At least 
100,000 events were acquired on an LSR Fortessa™ (BD) and analyzed with 
the FlowJo (BD) software.
Peptide synthesis, purification, and characterization for functional 
evaluation of CD8+ T cells 
Spike and RdRp peptide pools are listed in supplementary material 3A 
and their location at the protein is visualized in a 3D model in supplementary 
material 3B-C. Spike and RdRp peptide pools are based on the PDB 
structures 6VSB and 6M71, respectively. The peptides in the spike peptide 
pool are located on the surface area (the exposed region) of the glycoprotein 
(21). The peptides in the RdRp are sites involved in the protein folding which is 
part of the interaction of the complex formed by nsp12-nsp7-nsp8 (22). During 
this analysis, we did not have information on the patient’s HLA-I, therefore, 
PBMCs were stimulated with peptides located in different sites of the proteins.
Peptides were synthesized using a Liberty Blue™ automated microwave 
peptide synthesizer (CEM Corp., Matthews, NC, USA) following a standard 
9-fluorenylmethoxycarbonyl (Fmoc)/tert-butyl (tBu) protocol as previously 
described (23). Peptides were hydrolyzed with TFA/TIS/Water/DOT (proportion 
92.5:2.5:2.5:2.5) and purified by RP-HPLC; their purity and molecular weights 
were confirmed by electrospray mass spectrometry (ESI-MS), they were then 
lyophilized, reconstituted in sterile water (1 mg/ml), and stored at −20ºC until 
used.
Peptide stimuli and flow cytometry analysis of CD8+ T cells. Thawed 
PBMCs were cultured at a density of 4 ×106 cells/ml in RPMI-1640 medium 
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supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml of streptomycin, 
and 2 mM L-glutamine (complete medium; all from Sigma-Aldrich). The 
cells were stimulated with 1 ug/ml of both anti-CD28 (clone: CD28.2, 
eBioscience™), and anti-CD49d (clone: 9F10, eBioscience™) functional 
grade antibodies plus 10 μg/ml peptide pools (spike and RdRp). Cells 
stimulated only with anti-CD28 and anti-CD49d antibodies were used as 
negative controls. Stimulation with 1 ug/ml of peptide pools of Staphylococcal 
enterotoxin B (SEB) (Sigma-Aldrich) was used as a positive control. All groups 
of cells were incubated for 12 h at 37˚C in 5% CO2 in the presence of 10 μg/ml 
Brefeldin A and 7μM Monensin (both from Thermo Fisher) (24). 
After incubation, PBMCs were harvested, washed with PBS (Sigma-
Aldrich), and stained with conjugated antibodies against surface molecules 
CD3 and CD8, and with Fixable Viability Dye eFluor™ 506 (Thermo 
Fisher Scientific) at 4°C for 30 min. Afterwards, the cells were fixed and 
permeabilized with Foxp3 Fixation/Permeabilization Buffer (Thermo Fisher 
Scientific). Then, the following antibodies were added: anti-IL-2, anti-granzyme 
B, anti-perforin, anti-IFN-γ, anti-TNF-α, and anti-IL-10, and incubated at 4°C 
for 30 minutes (antibody details are shown in supplementary material 2). Cells 
were acquired in an LSR Fortessa™ flow cytometer using the BD FACSDiva™ 
software v 8.0.1 (BD). At least 100,000 events of the CD3+ T cells were 
recorded. To evaluate the polyfunctional response, a Boolean gating strategy 
was performed to create a full array of possible expression combinations of 
effector molecules up to 64 response patterns from the CD8+ T-cell gate. The 
data was reported after background subtraction (subtraction of the negative 
control) and correction. Background correction was defined according to the 
number of functions. For subsets with one and two functions, a level of 0.05% 
was considered as the threshold for a positive response. For the subsets with 
three and four function responses, the threshold was defined as 0.005%. In 
the case of five and six function responses, the threshold was defined as 
0.0005%. Subsequently, polyfunctionality was visually represented using the 
SPICE software v5.35 (25).
Ethics approval and consent to publication
All the necessary ethical considerations were observed. The study was 
approved by the ethics committee at Universidad de Antioquia. All research 
protocols adjusted to the principles of the Declaration of Helsinki. The donors 




The mild COVID19 case corresponded to a 59-year-old man residing in 
Medellín (JM). He had comorbidities such as hypertension, diabetes mellitus, 
and hypercholesterolemia, all of which were treated and controlled at the time 
of infection. He had traveled to southwest Europe (Portugal and Spain) with 
his family (including his two sons, A and JC, 24 and 35 years old, respectively) 
and returned to Colombia on March 12, 2020. Four days later, JM showed 
the first symptoms including headache, high dorsal pain, sored pharynx, mild 
coughing, and fever (38.2oC). In the following days, JM developed drowsiness, 
anorexia, and anosmia. The dorsal pain was moving downward in his back 
and he was treated with paracetamol. 
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On March 19, nasopharyngeal aspirates were taken from all family 
members. The RT-PCR tests were positive for JM, A, and JC. On March 25, a 
blood sample was drawn from JM (JM-1) and an additional nasopharyngeal 
aspirate was taken for viral isolation (SARS-CoV-2/human/Medellin/
UdeA1/2020). On this date, the SARS-CoV-2 RNA was detected at the cycle 
threshold (Ct) 19 in JM’s nasopharyngeal aspirate indicating a high viral load 
even after nine days of the onset of the symptoms.
In the following days, JM had prolonged asthenia and poorly defined 
discomfort in his back, but no clinical complications were observed. On March 
30, the RT-PCR for SARS-CoV-2 was negative for JM, A, and JC, and on April 
14 a convalescent blood sample was taken for antibody and immune testing 
(JM-2). By April 19, JM was fully recovered (phone follow-up) and on May 
28, blood samples from all family members (JM-3, A, and JC) were taken for 
immune characterization. The timeline is described in figure 1. 
Increased inflammatory cytokines during the acute symptomatic phase of 
infection
Higher mRNA levels of inflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α 
were observed during early symptomatic infection (JM-1) compared to healthy 
controls. These cytokine levels decreased in the convalescent phase (second 
and third sampling time) except for IL-6, whose levels increased again in the 
third sampling time (figure 2A-D). 
Regarding the asymptomatic but infected donors (A and JC), JC had 
a different profile and exhibited higher mRNA expression of IL-6 and IL-8 
compared to A and JM-3 at the same point of infection. Finally, the expression 
of IL-1β and IL-6 in the three family members remained higher than in the 
healthy controls even after two months of negative SARS-CoV-2 by RT-PCR.
ELISA quantification of IL-1β, IL-6, and IL-8 in plasma was undetectable 
in JM-3, A, and JC, as well as in the healthy controls, but they were detected 
during the acute symptomatic infection in JM (JM-1) (figure 2E-G).
Figure 1. Timeline of clinical evolution and sampling of a family cluster with SARS-CoV-2 infection. The family, composed by JM, his wife (not 
infected), and his sons A and JC likely acquired the SARS-CoV-2 infection during a trip to southwest Europe, but only JM was symptomatic. The time 
points at which samples were taken from the family members are indicated in the figure.
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NK cells phenotype
We evaluated the main two NK cell subpopulations, CD56bright (representing 
the cytokine-producer subset, mainly IFN-γ), and CD56dim (cytotoxic cells), as 
well as terminally differentiated NK cells identified by the expression of the 
maturation marker CD57. Adaptive NK cells, which are terminally differentiated 
memory-like NK cells with high expression of activating receptor NKG2C, were 
also included in the analysis. The percentage of CD56bright NK cells increased 
over time in JM (figure 3A). The frequency of the other NK cell subsets in 
JM’s samples did not differ considerably in any of the points in time (figure 
3B-D). When the other family members were analyzed, a lower frequency of 
CD56bright NK cells was observed in JC compared to JM-3 and A (figure 3A). 
Interestingly, the percentage of CD56dim, CD57+, and NKG2C+ adaptive NK 
cells was lower in A and JC compared to JM at all evaluated times (figure 3D).
Decreased NK activity during the symptomatic SARS-CoV-2 infection
The cytotoxic capacity was evaluated by co-cultures of the K562 cell line 
with PBMCs from each donor. A representative scheme of the cytotoxicity 
assessment is shown in figure 3E. Compared with the controls, decreased 
Figure 2. Proinflammatory cytokine expression. The mRNA expression of TNF-α (A), IL-1β (B), IL-6 (C), and IL-8 (D) was evaluated by 
real time RT-PCR in PBMCs from the family members and healthy controls (n=3). The results are presented as relative transcripts units 
(RTU) normalized over the expression of the PGK reference gene. Protein levels of IL-1β (E), IL-6 (F), and IL-8 (G) were evaluated by 
ELISA in plasma from the family members and healthy controls. DL: detection limit 
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Figure 3. NK cell phenotype and cytotoxicity. Percentage of cytokine-producer 
CD56bright (A), cytotoxic CD56dim (B), mature CD56dim CD57+(C), and adaptive 
CD56dim CD57+ NKG2C+ (D) NK cells subsets in JM, A, and JC. JM-1, JM-2, JM-3 
correspond to three different JM sampling times (see figure 1 for details on sampling 
times). The cytotoxicity was expressed as the percentage of K562 DIOC-6- PI+ cells: 
(E) Representative gate of target cells (K562) selected by eFluor670 expression. (F) 
Percentage of cytotoxicity for each subject compared with the respective age- and 
sex-paired control
cytotoxic NK cells activity was observed in JM, with the lowest activity 
occurring during the symptomatic acute infection (JM-1) (figure 3F). Although 
NK cell activity seemed to increase in the convalescent phase (JM-2), 
it remained lower than the age- and sex-paired control (figure 3F). No 
differences were observed in asymptomatic subjects (A and JC) compared to 
their age- and sex-paired healthy controls.
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Anti-SARS-CoV-2 antibodies
Indirect immunofluorescence. Specific antibodies against SARS-CoV-2 
were detected in family members’ sera by IFA with serum dilutions ranging 
from 1:5 to 1:80. JM showed titers of specific anti-SARS-CoV-2 antibodies of 
1:5 at the first sample time and increased to 1:20 at the third sample time. A 
and JC’s titers were 1:5 and 1:10, respectively.
Neutralizing antibodies. Once the specific anti-SARS-CoV-2 antibodies 
were detected in the family cluster sera, the titers of the neutralizing 
antibodies were established by PRNT50 at 1:20, 1:200, and 1:2000 serum 
dilutions on VeroE6 cells. 
The second sample from JM (JM-2) showed a plaque reduction of 51.3% at 
1:200 dilution while his third sample (JM-3) showed a slight decrease in the titer 
(40.4% at 1:200 dilution). A’s titer was close to 1:200 (46.6% plaque reduction) 
while JC’s was <1:20 (48.3% plaque reduction) (supplementary material 4).
T cells activation phenotype 
The percentage of CD4+ and CD8+ T cells expressing HLA-DR, CD38, 
and CD69 activation markers, as well as the Ki-67 proliferation marker, was 
measured on PBMCs obtained from all family members. 
We found a slight increase in the percentages of CD38+ HLA-DR- CD4+ 
T cells in A (64.6%) and JC (56.4%) compared to JM-3 (42.3%) (figure 4A). 
In contrast, CD69+ CD4+ T cell frequency was similar for JM-3 (14.5%), A 
(15%), and JC (16%), but such percentages were higher compared to those 
observed in healthy controls (media ± SD; 7.6 ± 2.6%) (figure 4A).
Figure 4. Activation 
phenotype of T cells. 
We explored the co-
expression of CD38 
and HLA-DR, as well as 
the percentages of the 
proliferation marker Ki-67 
and the activation marker 
CD69 in CD4+ (A) and 
CD8+ (B) cells from the 
family members in the 
convalescent phase and 
healthy controls (n=3).
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On the other hand, similar percentages of CD38+ HLA-DR- CD8+ T cells 
were found for JM-3 (57.2%), A (55.9%), and JC (55.3%), which were higher 
compared to those observed in healthy controls (37.1 ± 4.0%) (figure 4B). On 
the contrary, the percentage of CD38- HLA-DR+ CD8+ T cells was lower in family 
members during the recovery phase compared to healthy controls (15.2 ± 5.7%), 
and much lower in JM-3 (2.8%) compared to A (4.7%) and JC (7.9%) (figure 4B).
Regarding the Ki-67 proliferation marker, no differences were observed in 
CD4+ T cells nor CD8+ T cells between family members and healthy controls.
Frequency and functional profile of antigen-specific SARS-CoV-2 CD8+ T 
cells 
The functional profile of antigen-specific SARS-CoV-2 CD8+ T cells 
was established through the evaluation of cytokine and cytotoxic molecule 
expression in response to spike and RdRp peptide pools (supplementary 
material 3). SARS-CoV-2 specific cytokine-producing CD8+ T cells in response 
to both peptide pools were observed mainly at the first follow-up point in time 
for JM when he was still symptomatic; lower or undetectable frequencies were 
observed at days 30 (JM-2) and 73 (JM-3) after the onset of the symptoms, as 
well as in asymptomatic individuals (A and JC) 73 days after diagnosis (figure 
5A-D). While SARS-CoV-2 specific IL-10-producing CD8+ T cells were more 
frequent in JC than A and JM-3, A had a higher percentage of SARS-CoV-2 
specific IFN-γ- and TNF-α-producing CD8+ T cells compared to A and JM-3, 
mainly in response to spike peptides (figure 5A-D).
Figure 5. CD8+ T cell response to SARS-
CoV-2 peptide pools. Frequency of CD8+ 
T cells positive for cytokines IFN-γ (A), IL-2 
(B), TNF-α (C), and IL-10 (D), as well as 
degranulation marker CD107a along with 
granzyme B (E) and perforin (F). Each bar 
represents the CD8+ T cell response in an 
individual in response to spike (white bars), 
RdRp (gray bars) peptide pools or SEB (black 
bars) after subtraction of the negative control. 
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Regarding the capacity of CD8+T cells to produce de novo granzyme B 
and perforin (evaluated by the coexpression of CD107a with each cytotoxic 
molecule) in response to both peptide pools, CD107a+ granzymeB+ and 
perforin+ CD8+ T cells were detectable up to 73 days after the onset of 
symptoms with their highest at day 30 (figure 5E, F). Both asymptomatic 
individuals (A and JC) developed a cytotoxic response which remained for 
up to 73 days after diagnosis (figure 5E-F), but no differences were observed 
among the family members. 
Additionally, we evaluated the quality of SARS-CoV-2-CD8+ T cell response 
considering that the polyfunctionality of CD8+ T cells has been associated with 
better control of viral infection. During JM’s follow up, the response against 
spike peptides changed from a predominant monofunctional response, at the 
expense mainly of IL-10 (JM-1), to a higher proportion of bifunctional cells 
where CD107a+granzymeB+ and CD107a+perforin+ profile was dominant (JM-2 
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Figure 6. Polyfunctional 
CD8+ T cell response to 
SARS-CoV-2 spike and RdRp 
peptides. Pie charts represent 
the polyfunctional profile of 
CD8+ T cells in response to 
the spike in JM’s follow-up 
(A-C), and asymptomatic A 
(D), and JC (E), as well as 
the polyfunctional profile of 
CD8+ T cells in response to 
RdRp in JM’s follow-up (F-H) 
and asymptomatic A (I) and 
JC (J). Arcs depict molecule 
make-up within the pie slice. 
The combination of functions 
evaluated is indicated by pie 
chart colors.
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With regard to the response to spike peptides in asymptomatic 
individuals about 73 days post-diagnosis, A exhibited a major proportion 
of the predominant pattern of bifunctional responses dominated by 
CD107a+granzymeB+ and CD107a+perforin+ CD8+ T cells compared to JM-3 
and JC. However, the monofunctional response in asymptomatic individuals 
consisted of perforin whereas in JM-3 it was mainly granzyme B (figure 6C-E). 
Concerning RdRp peptides, we observed a high proportion of cells 
exhibiting two functions with cytotoxic profile followed by the monofunctional 
responses at the expense of all the cytokines evaluated when the individual 
was symptomatic (JM-1) (figure 6F). However, after 30 days of follow up, the 
highest proportion of two functions had a cytotoxic profile (figure 6G) whereas 
at day 73, monofunctional responses predominated but still at the expense of 
perforin (figure 6H). Besides, donor A exhibited a major proportion of CD8+ T 
cells with monofunctional responses compared to JM-3 and JC (figures 6H-J). 
Again, the bifunctional profile was dominated by a cytotoxic profile in both 
asymptomatic individuals (figures 6I-J). 
Altogether, these results suggest an association between the development 
of the cytotoxic capacity of antigen-specific SARS-CoV-2-CD8+ T cells and 
mild disease or even asymptomatic infection.
Discussion
COVID-19 infection has been characterized for highly variable disease 
manifestations (26,27) and immune response elicited (28,29). Here, 
we evaluated the immunological profile of a family cluster including a 
mild COVID-19 case (JM) and two asymptomatic infections (A and JC). 
Interestingly, a more robust immune response characterized by higher IFN-
γ-producer CD56bright NK cells, higher neutralizing antibodies titer, and higher 
percentage of SARS-CoV-2 specific IFN-γ- and TNF-α-producing CD8+ T 
cells were observed in donor A compared to JC, both with common genetic 
and demographic characteristics, infected around the same time, and most 
likely with the same viral strain. It is important to point out that A was 11 
years younger than JC, although both are considered young adults, and this 
difference should not account for the observed results.
Despite neutralizing antibodies have been correlated with protection 
against SARS-CoV-2 infection (30,31), these are not strictly required to clear 
the SARS-CoV-2 infection as observed in the asymptomatic neutralizing-
negative subject JC, and as previously suggested for young people (aged 
16-30) (32). Similarly, donor A showed low neutralizing antibody levels, which 
raises the following question: What is the protection factor in individuals 
without significant humoral responses? The symptomatic donor JM had 
a reduction in neutralizing antibody titers in the convalescent period, as 
previously reported (33).
Inflammation is a hallmark of COVID19 severe cases in contrast with 
lower immune activation that seemingly characterizes asymptomatic cases 
(33). Proinflammatory cytokines measured by PCR and ELISA in JM peaked 
during the acute infection and decreased in the convalescent phase, at least in 
plasma, to levels near those found in healthy controls. These results are in line 
with previous reports, especially those for IL-6 and IL-8 (34,35). In contrast, a 
previous report did not find differences in IL-1b or TNF-a levels when comparing 
infected versus uninfected donors (34). Small differences were observed in the 
convalescent phase among JM (recovered from symptomatic infection), A, and 
99
Immune profile during SARS-CoV-2 infectionBiomédica 2021;41(Supl.2):86-102
JC (recovered from asymptomatic infection) suggesting that proinflammatory 
cytokines are restored to baseline levels after the virus is cleared. 
Antiviral NK cells also seem to be altered during acute SARS-CoV-2 
infection since the frequency of IFN-γ-producer CD56bright NK cells and 
cytotoxic activity against K562 cells was lower during this phase in JM-1 
compared to JM-2, and JM-3 (30 and 73 days after symptoms onset, 
respectively), and to A and JC in the convalescent phase. 
No changes in the adaptive NKG2C+ NK cells frequency as shown by 
effectively mediated antibody-dependent effector functions and cytokine 
production (10,11) in the hematopoietic stem cell transplantation setting, the 
presence of donor activating KIRs (aKIRs) were observed during JM’s follow-
up. We want to highlight that the frequency of this cell subpopulation was 
higher in JM, an older subject, compared to donors A and JC. Indeed, the 
frequency of this NK cells subset has been reported to increase with age (36).
In contrast to cytokines and NK cells, the frequency of activated CD69+ 
CD4+ and CD38+ CD8+ T cells remained higher in the convalescent phase, 
regardless of infection symptomatic or asymptomatic nature, compared to 
healthy controls. This aspect would relate to persistent hyperactivation of 
the T cell profile despite viral clearance or due to a SARS-CoV-2 specific 
response (37). Indeed, whereas cytokine-producing CD8+ T cells were mainly 
observed during the symptomatic acute infection in JM, and lower or absent 
during the convalescent phase in JM, A, and JC, CD107a+ granzymeB+ and 
perforin+ CD8+ T cells remained detectable up to 73 days after diagnosis in all 
family members. These results are similar to a previous report showing lower 
cytokine expression on CD8+ T cells in the mild disease compared with severe 
cases, although the activation markers remained highly expressed suggesting 
a lack of T cell response contraction (37).
During JM’s follow-up, we observed a higher frequency of SARS-CoV-2-
specific-CD8+T cells evaluated through the production of cytokines, which 
declined after the resolution of the infection as previously described in a 
preprint (38). Importantly, we observed that spike-CD8+T cells in JM produced 
lower amounts of granzyme and perforin during the acute phase of the 
infection in comparison to the following time points, which suggests a reduced 
cytotoxic capacity of specific-CD8+ T cells in COVID-19 patients consistent 
with previous reports (38,39).
We also evaluated the polyfunctionality of CD8+ T cells, a correlate of immune 
protection, including not only the production of cytokines, as in other reports, 
but also the production of cytotoxic molecules. The polyfunctionality of SARS-
CoV-2-specific-CD8+ T cells in JM during the acute phase of the infection was 
mainly monofunctional as has been suggested for symptomatic patients (38). 
However, after 30 days of the onset of the symptoms, we observed an increase 
in the frequency of bifunctional cells (secreting granzyme B and perforin), which 
declined after 73 days of symptoms onset. In this sense, one study showed a 
decrease in the functional diversity of T cells in patients compared with healthy 
controls (40). However, other authors have reported polyfunctionality, particularly 
by CD4+ T cells expressing TNF-a, IL-2, and IL-17 (41).
The frequency of specific-CD8+ T cells capable of producing cytotoxic 
molecules in asymptomatic individuals was similar to that observed in JM during 
the convalescent phase. Indeed, the polyfunctional response of asymptomatic 
individuals was mainly mono- and bifunctional with prevalent production of 
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cytotoxic molecules. This suggests that the cytotoxic capacity of spike-specific-
CD8+ T cells may be correlated to protection in SARS-CoV-2 infection. 
Our results suggest a strong inflammatory response during mild 
COVID-19 disease with a reduction of CD56bright NK cells subset during 
the symptomatic phase and lower cytotoxic response of these cells. 
Compared with the asymptomatic infection and uninfected individuals, we 
observed a higher frequency of dysfunctional CD38+ HLA-DR- CD8+ T cells 
subpopulation during the symptomatic phase. Additionally, CD8+ T cells had 
a predominant monofunctional response with high IL-10 production in mild 
COVID-19 but a bifunctional response dominated by CD107a+granzymeB+ 
and CD107a+perforin+ CD8+ T cells in asymptomatic infection suggesting an 
important role of spike-specific-CD8+ T cells. However, our study had a limited 
sample size and few SARS-CoV-2 peptides were analyzed, so additional 
studies comparing immune profiles in individuals with different progression 
patterns could provide information to develop immunotherapy strategies. 
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